Open in PodwiseOpen

Podcast cover

BiotechTV · News

BiotechTV - News

This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.

Episodes

From London: Yellowstone Biosciences is leveraging an Oxford AML patient biobank to develop an HLA Class II platform of T-cell engagers

From London: Edward Hodgkin is the Executive Chair of Syncona's 'Slingshot', a platform that takes early stage science from academic labs that isn't ready to be a company and helps matures it

From London: Purespring Therapeutics is developing a gene therapy that is delivered locally to the podocytes in the kidney and aims to treat IgAN as its initial indication

From London: Resolution Therapeutics is in the clinic with its engineered regenerative macrophage therapy to treat end stage liver disease

From London: With science from the Francis Crick Institute, ALTx Therapeutics launched with £12.55m last month to target cancers that rely on the Alternative Lengthening of Telomeres (ALT)

From London: iOnctura is developing its allosteric PI3Kδ for uveal melanoma - an indication that has seen progress but still has much unmet need

From London: Spur Therapeutics is an a phase 3 for its gene therapy for Gaucher Disease - using a unique construct that allows them to have a lower dose than other gene therapies

From London: Beacon Therapeutics has a phase 3 trial scheduled to read this year for its gene therapy for X-Linked Retinitis Pigmentosa (XLRP)

From London: Syncona CEO Chris Hollowood discusses the firm's public and private funds, and the state of investing in life sciences today from the firm's Capital Markets Day

Checking in with Menlo Ventures' Partner Greg Yap to get his take on the latest trends in AI in healthcare

Earli, which raised $105M in two rounds, is developing 'Cancer-Activated Promoters' that are set off by cancer-specific transcription factors and turn tumor cells into therapeutic payload factories

Barclays Miami: MannKind CEO Michael Castagna shares an update on the company, including a recent $360M acquisition, and two regulatory reviews at FDA that have decision dates over the coming months

Barclays Miami: Barclays' Senior Biotech Analyst Etzer Darout shares his take on biotech and discusses companies he covers that have been in the news

Barclays Miami: Zealand Pharma CEO Adam Steensberg makes the case for last week's amylin data

Barclays Miami: Barclays' Head of Healthcare M&A shares his take on the current environment of dealmaking

Reunion Neuroscience recently received Breakthrough Therapy Designation from FDA for its psychedelic based treatment for postpartum depression (PPD)

Barclays Miami: Ocular Therapeutix's Chair Pravin Dugel discusses feedback he has been receiving on SOL-1 since announcing it last month

Barclays Miami: Xencor CEO Bassil Dahiyat discusses the company's internal pipeline and how bi-specifics and other modalities are engineered to be increasingly sophisticated and more precise

Barclays Miami: Recludix believes the time is right in science to drug SH2 domains. The company's lead programs target STAT6 and BTK

Barclays Miami: Barclays' Senior Biotech Analyst Ellie Merle shares her take on biotech and thoughts on companies she covers that have been in the news

Page 5

Follow this podcast in Podwise

Sign in to get AI summaries, transcripts and mind maps for any episode, including new ones.

Open in Podwise